Johnson & Johnson (JNJ) units Actelion Pharmaceuticals and Janssen Research & Development have agreed to pay $65 million to settle a proposed antitrust class action alleging overcharging for the pulmonary artery hypertension drug Tracleer, Reuters reported Friday.

The Government Employees Health Association and other entities that paid or reimbursed payments made by their members for Tracleer alleged in the lawsuit that the companies delayed competition for a generic version of the drug, according to the report.

The preliminary settlement, which covers Tracleer purchases in 31 states, the District of Columbia and Puerto Rico from December 2015 to September 2024, was filed Wednesday in Maryland federal court and requires approval from a judge, Reuters said.

Johnson & Johnson did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 238.77, Change: -0.86, Percent Change: -0.36